Ainos, Inc. - 8-K Filing
Ainos entered a $10M global exclusive license agreement with BioPhoenix for VELDONA® technology in Sjögren’s Disease and Thrombocytopenia. (Items: 1.01 Entry into a Material Definitive Agreement On September 24, 2026 (the “Effective Date”), Ainos, Inc, 7.01 Regulation FD Disclosure On September 28, 2026, the Company announced the execution of the License Agreement with BioPhoenix, 9.01 Financial Statement and Exhibits (d) Exhibits)
Tickers: $AIMD